ZIVO · Zivo Bioscience, Inc.
$0.67
At close · Nov 27
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
ZIVO metrics
33 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.67
Market cap
$16.53M
Price action
19 metricsPrice change (1W)
-43.7%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
5.5
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
42,210
Relative volume
5.4
Average dollar volume
$54,094
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
3.89M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
79.1×
reciprocal yield 1.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-51.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
31.7%
Operating margin
-4,045.7%
Trailing 12 months
Net margin
-4,059.7%
Gross profit (TTM)
$66,210
Operating profit (TTM)
−$8.46M
Net income (TTM)
−$8.49M
Trailing 12 months
Diluted EPS (TTM)
$-2.13
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+108.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$209,025
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-1,516.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$8.95M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$57,222
Total assets
$559,452
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$3.08M
Capital expenditures (TTM)
—
R&D (TTM)
$3.70M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
1,768.1%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged